871224-64-5

• 常用中文名：阿莫伦特
• 常用英文名：Almorexant
• CAS号：871224-64-5
• 分子式：C₂₉H₃₁F₃N₂O₃
• 分子量：512.563
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 食欲素受体(OX受体)
• 发布时间：2018-08-09 23:03:30
• 更新时间：2024-01-02 19:33:49
• Almorexant(ACT078573)是OX1和OX2受体拮抗剂,Ki分别为1.3和0.17 nM。

名称

• 中文名: 阿莫伦特
• 英文名: (R)-2-((R)-6,7-dimethoxy-1-(4-(trifluoromethyl)phenethyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide
• 英文别名: (2R)-2-[(1S)-6,7-Dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydro-2(1H)-isoquinolinyl]-N-methyl-2-phenylacetamide; (R)-2-{(S)-6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenylacetamide; Almorexant [inn]; [3H]-Almorexant; 2(1H)-Isoquinolineacetamide, 3,4-dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-, (αR,1S)-; AlMorexant HCl; 2(1H)-Isoquinolineacetamide, 3,4-dihydro-6,7-dimethoxy-N-methyl-α-phenyl-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-, (αR,1R)-; (2R)-2-((1S)-6,7-Dimethoxy-1-{2-(4-(trifluoromethyl)phenyl)ethyl}-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide; Almorexant; (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide; ((2R)-2-((1S)-6,7-dimethoxy-1-(2-(4-trifluoromethylphenyl)-ethyl)-3,4-dihydro-1H-isoquinolin-2-yl)-N-methyl-2-phenylacetamide); (2R)-2-[(1R)-6,7-Dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydro-2(1H)-isoquinolinyl]-N-methyl-2-phenylacetamide

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 620.4±55.0 °C at 760 mmHg
• 分子式: C₂₉H₃₁F₃N₂O₃
• 分子量: 512.563
• 闪点: 329.0±31.5 °C
• 精确质量: 512.228699
• PSA: 50.80000
• LogP: 5.89
• 蒸汽压: 0.0±1.8 mmHg at 25°C
• 折射率: 1.554
• 储存条件: -20°C，密闭，干燥

生物活性

• 描述: Almorexant(ACT078573)是OX1和OX2受体拮抗剂,Ki分别为1.3和0.17 nM。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 食欲素受体(OX受体)
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Cruz HG, et al. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. CNS Drugs. 2014 Apr;28(4):361-72.

  [2]. Malherbe P, et al. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol. 2009 Sep;76(3):618-31.

  [3]. Sifferlen T, et al. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1539-42.

  [4]. Black SW, et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep. 2013 Mar 1;36(3):325-36.

  [5]. Dayot S, et al. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget. 2018 Jan 9;9(6):6952-6967.

合成路线

769172-81-8 871224-68-9 ~% 871224-64-5

文献：WO2009/83899 A2, ; Page/Page column 28 ; WO2009/83903 A1, ; Page/Page column 28 ;

871224-77-0 593-51-1 ~% 871224-64-5

文献：WO2005/118548 A1, ; Page/Page column 28 ; WO 2005/118548 A1

769172-81-8 51685-62-2 ~% 871224-64-5

文献：WO2005/118548 A1, ; Page/Page column 29 ; WO 2005/118548 A1

上下游产品

上游产品  5
769172-81-8 871224-68-9 871224-77-0 593-51-1
51685-62-2
下游产品  0